Related references
Note: Only part of the references are listed.Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma
Steven B. Maron et al.
CANCER DISCOVERY (2018)
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights
Rodrigo Dienstmann et al.
MOLECULAR ONCOLOGY (2017)
Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer
Shuwei Li et al.
JOURNAL OF CANCER (2017)
Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors
Thomas Tuxen Poulsen et al.
CLINICAL CANCER RESEARCH (2017)
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Daniel V. T. Catenacci et al.
GASTRIC CANCER (2016)
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
Paolo Nuciforo et al.
MOLECULAR ONCOLOGY (2016)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trialsaEuro
M. J. Overman et al.
ANNALS OF ONCOLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Aberrant Expression of Calretinin, D2-40 and Mesothelin in Mucinous and Non-Mucinous Colorectal Carcinomas and Relation to Clinicopathological Features and Prognosis
Abd AlRahman Mohammad Foda et al.
PATHOLOGY & ONCOLOGY RESEARCH (2016)
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S. Hong et al.
CANCER DISCOVERY (2016)
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
Wafik S. El-Deiry et al.
CANCER BIOLOGY & THERAPY (2015)
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
Nicola Personeni et al.
CLINICAL COLORECTAL CANCER (2015)
Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer
Michel B. Choueiri et al.
PLOS ONE (2015)
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy
Zheng Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
Daniel V. T. Catenacci et al.
PLOS ONE (2014)
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
P. Li et al.
BRITISH JOURNAL OF CANCER (2013)
Targeting the RAS oncogene
Asami Takashima et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor Tissue
Todd Hembrough et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and-2 clinical trials
P. P. Grimminger et al.
PHARMACOGENOMICS JOURNAL (2012)
Keratin 7 expression in colorectal cancer - freak of nature or significant finding?
Lars Harbaum et al.
HISTOPATHOLOGY (2011)
Multifactorial Approach to Predicting Resistance to Anthracyclines
Christine Desmedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Differential Proteomic Analysis of Late-Stage and Recurrent Breast Cancer from Formalin-Fixed Paraffin-Embedded Tissues
Nicholas W. Bateman et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Performance Metrics for Liquid Chromatography-Tandem Mass Spectrometry Systems in Proteomics Analyses
Paul A. Rudnick et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
Mass spectrometry in high-throughput proteomics: ready for the big time
Tommy Nilsson et al.
NATURE METHODS (2010)
mTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues
Leroi V. DeSouza et al.
PROTEOMICS (2010)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma
Terri A. Addona et al.
NATURE BIOTECHNOLOGY (2009)
LC/MS-Based Quantitative Proteomic Analysis of Paraffin-Embedded Archival Melanomas Reveals Potential Proteomic Biomarkers Associated with Metastasis
Sharon K. Huang et al.
PLOS ONE (2009)
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
Evangelia Razis et al.
BMC CANCER (2008)
Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival
Hirozumi Sawai et al.
BMC GASTROENTEROLOGY (2008)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate
Harvey J. Motulsky et al.
BMC BIOINFORMATICS (2006)
Proteomic analysis of formalin-fixed prostate cancer tissue
BL Hood et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin
E Compérat et al.
MODERN PATHOLOGY (2005)
The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas
J Moldvay et al.
PATHOLOGY & ONCOLOGY RESEARCH (2004)
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
Y Shirota et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
